Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 84.90
+2.30 (2.78%)
Apr 29, 2026, 4:08 PM HKT
Innovent Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 13,042 | 9,422 | 6,206 | 4,556 | 4,270 | Upgrade
|
| Revenue | 13,042 | 9,422 | 6,206 | 4,556 | 4,270 | Upgrade
|
| Revenue Growth (YoY) | 38.42% | 51.82% | 36.21% | 6.71% | 11.08% | Upgrade
|
| Cost of Revenue | 3,075 | 2,412 | 1,807 | 1,382 | 1,224 | Upgrade
|
| Gross Profit | 9,966 | 7,010 | 4,399 | 3,175 | 3,045 | Upgrade
|
| Selling, General & Admin | 6,640 | 5,085 | 3,851 | 3,426 | 3,426 | Upgrade
|
| Research & Development | 2,624 | 2,202 | 2,112 | 2,871 | 2,323 | Upgrade
|
| Operating Expenses | 9,264 | 7,287 | 5,963 | 6,297 | 5,749 | Upgrade
|
| Operating Income | 702.11 | -276.57 | -1,564 | -3,123 | -2,703 | Upgrade
|
| Interest Expense | -79.6 | -67.65 | -98.62 | -101.7 | -62.46 | Upgrade
|
| Interest & Investment Income | 438.69 | 423.45 | 452.84 | 189.54 | 151.76 | Upgrade
|
| Earnings From Equity Investments | -96.79 | -41.01 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -246.83 | 130.28 | 60.82 | 752.05 | -198.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 117.36 | 76.13 | 90 | 107.32 | 46.78 | Upgrade
|
| EBT Excluding Unusual Items | 834.94 | 244.64 | -1,059 | -2,176 | -2,766 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.56 | 179.03 | 30.81 | 5.1 | 125.02 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.57 | -22.99 | -0.95 | 0.06 | -0.71 | Upgrade
|
| Asset Writedown | - | -479.3 | -115.36 | - | - | Upgrade
|
| Pretax Income | 838.92 | -78.62 | -1,144 | -2,170 | -2,642 | Upgrade
|
| Income Tax Expense | 25.36 | 16.01 | -116.5 | 8.8 | 87.04 | Upgrade
|
| Earnings From Continuing Operations | 813.57 | -94.63 | -1,028 | -2,179 | -2,729 | Upgrade
|
| Net Income | 813.57 | -94.63 | -1,028 | -2,179 | -2,729 | Upgrade
|
| Net Income to Common | 813.57 | -94.63 | -1,028 | -2,179 | -2,729 | Upgrade
|
| Shares Outstanding (Basic) | 1,677 | 1,627 | 1,560 | 1,490 | 1,456 | Upgrade
|
| Shares Outstanding (Diluted) | 1,741 | 1,627 | 1,560 | 1,490 | 1,456 | Upgrade
|
| Shares Change (YoY) | 6.98% | 4.35% | 4.67% | 2.37% | 7.27% | Upgrade
|
| EPS (Basic) | 0.48 | -0.06 | -0.66 | -1.46 | -1.87 | Upgrade
|
| EPS (Diluted) | 0.47 | -0.06 | -0.66 | -1.46 | -1.88 | Upgrade
|
| Free Cash Flow | - | 321.36 | -971.58 | -2,816 | -3,090 | Upgrade
|
| Free Cash Flow Per Share | - | 0.20 | -0.62 | -1.89 | -2.12 | Upgrade
|
| Gross Margin | 76.42% | 74.40% | 70.89% | 69.67% | 71.32% | Upgrade
|
| Operating Margin | 5.38% | -2.94% | -25.20% | -68.54% | -63.31% | Upgrade
|
| Profit Margin | 6.24% | -1.00% | -16.56% | -47.83% | -63.91% | Upgrade
|
| Free Cash Flow Margin | - | 3.41% | -15.65% | -61.80% | -72.38% | Upgrade
|
| EBITDA | 1,003 | 23.99 | -1,288 | -2,878 | -2,538 | Upgrade
|
| EBITDA Margin | 7.69% | 0.26% | -20.76% | -63.16% | -59.44% | Upgrade
|
| D&A For EBITDA | 300.56 | 300.56 | 275.6 | 245.09 | 165.4 | Upgrade
|
| EBIT | 702.11 | -276.57 | -1,564 | -3,123 | -2,703 | Upgrade
|
| EBIT Margin | 5.38% | -2.94% | -25.20% | -68.54% | -63.31% | Upgrade
|
| Effective Tax Rate | 3.02% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.